论文部分内容阅读
目的观察在胃癌及癌前病变中RUNX3的表达变化。方法采用免疫组织化学方法检测5组观察对象:浅表胃炎组、萎缩胃炎组、肠化生组、非典型增生组、胃癌组,每组20例,观察RUNX3的表达变化。结果与浅表性胃炎组、萎缩性胃炎组、肠化生组比较,胃癌组RUNX3阳性表达率明显减低(χ2值分别为12.23,12.29,10.0 8,P<0.05)。浅表性胃炎组、萎缩性胃炎组、肠化生三组间比较差异无统计学意义(χ2值1.03,P>0.05),非典型增生组与胃癌组比较差异无统计学意义(χ2值3.3,P>0.0 5)。结论 RUNX3的表达缺失可能在胃癌的发生发展中起一定的作用。
Objective To observe the expression of RUNX3 in gastric cancer and precancerous lesions. Methods Immunohistochemistry was used to detect five groups of subjects: superficial gastritis group, atrophic gastritis group, intestinal metaplasia group, atypical hyperplasia group and gastric cancer group, with 20 cases in each group. The expression of RUNX3 was observed. Results Compared with superficial gastritis group, atrophic gastritis group and intestinal metaplasia group, the positive expression rate of RUNX3 in gastric cancer group was significantly decreased (χ2 = 12.23,12.29,10.08, P <0.05). There was no significant difference between the superficial gastritis group, the atrophic gastritis group and the intestinal metaplasia group (χ2 = 1.03, P> 0.05), but there was no significant difference between the atypical hyperplasia group and the gastric cancer group (χ2 = 3.3 , P> 0.0 5). Conclusion The loss of RUNX3 expression may play a role in the occurrence and development of gastric cancer.